S-8 1 d592872ds8.htm S-8 S-8

As filed with the Securities and Exchange Commission on August 9, 2018

Registration No. 333-                

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

Albireo Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   90-0136863

(State or other jurisdiction of

incorporation or organization)

  

(I.R.S. Employer

Identification No.)

 

10 Post Office Square, Suite 502 South, Boston, Massachusetts   02109
(Address of principal executive offices)   (Zip code)

Albireo Pharma, Inc. 2018 Equity Incentive Plan

Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan

(Full title of the plans)

Thomas A. Shea

Chief Financial Officer and Treasurer

Albireo Pharma, Inc.

10 Post Office Square, Suite 502 South

Boston, Massachusetts 02109

(857) 254-5555

(Name, address and telephone number, including area code, of agent for service)

Copy to:

 

Megan N. Gates, Esq.

John P. Condon, Esq.

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

One Financial Center

Boston, Massachusetts 02111

(617) 542-6000

Facsimile: (617) 542-2241

  

Jason G. Duncan, Esq.

General Counsel and Secretary

Albireo Pharma, Inc.

10 Post Office Square, Suite 502 South

Boston, Massachusetts 02109

(857) 254-5555

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer   ☐    Accelerated filer   ☒
Non-accelerated filer   ☐ (Do not check if a smaller reporting company)    Smaller reporting company   ☐
     Emerging growth company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☐

 

 

CALCULATION OF REGISTRATION FEE

 

 

Title of

Securities to be

Registered

  

Amount to be

Registered (1)

  

Proposed

Maximum

Offering Price

Per Share

  

Proposed

Maximum

Aggregate

Offering Price

  

Amount of

Registration Fee

Common Stock, $0.01 par value per share

   2,506,088 shares   $30.07 to $30.89 (2)     $75,721,777.16 (2)     $9,427.37

 

 

(1)

The number of shares of common stock, par value $0.01 per share (“Common Stock”), of Albireo Pharma, Inc. (the “Registrant”) stated above consists of (i) 2,206,088 shares issuable under the Registrant’s 2018 Equity Incentive Plan (the “2018 Plan”) and (ii) 300,000 shares issuable under the Registrant’s 2018 Employee Stock Purchase Plan (the “2018 ESPP,” and together with the 2018 Plan, the “Plans”). The maximum number of shares which may be sold upon the exercise of such options or issuance of stock-based awards granted under the Plans is subject to adjustment in accordance with certain antidilution and other provisions of the Plans. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement covers, in addition to the number of shares stated above, an indeterminate number of shares which may be subject to grant or otherwise issuable after the operation of any such antidilution and other provisions.

(2)

Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(c) and Rule 457(h) promulgated under the Securities Act. The offering price per share and the aggregate offering price for shares (a) issuable upon the exercise of outstanding options granted under the 2018 Plan are based upon the weighted-average exercise price of such outstanding options and (b) reserved for future grant or issuance under the 2018 Plan and the 2018 ESPP are based on the average of the high and the low price of the Registrant’s Common Stock as reported on The Nasdaq Capital Market as of a date (August 7, 2018) within five business days prior to filing this Registration Statement. The chart below details the calculation of the registration fee:

 

Securities

    Number of
Shares		      Offering Price
Per Share (2)		     Aggregate
Offering Price		  

Shares issuable upon the exercise of outstanding options granted under the 2018 Plan

      443,550      $ 30.89  (2)(a)    $ 13,701,259.50  

Shares reserved for future grant under the 2018 Plan

      1,762,538      $ 30.07  (2)(b)    $ 52,999,517.66  

Shares reserved for future issuance under the 2018 ESPP

      300,000      $ 30.07  (2)(b)    $ 9,021,000.00  

Proposed Maximum Aggregate Offering Price

         $ 75,721,777.16  

Registration Fee

         $ 9,427.37  

 

 

 

EXPLANATORY NOTE

This Registration Statement registers (i) 2,206,088 shares of common stock, par value $0.01 per share, of the Registrant (the “Common Stock”) reserved for issuance under the Registrant’s 2018 Equity Incentive Plan (the “2018 Plan”) and (ii) 300,000 shares of Common Stock reserved for issuance under the Registrant’s 2018 Employee Stock Purchase Plan (the “2018 ESPP,” and together with the 2018 Plan, the “Plans”). This Registration Statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 of the Registrant relating to an employee benefit plan is effective (File No. 333-215264). The information contained in the Registrant’s registration statement on Form S-8 (File No. 333-215264), except for Item 8 “Exhibits,” is hereby incorporated by reference pursuant to General Instruction E of Form S-8.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8. Exhibits.

 

Exhibit
Number		   

Exhibit Description

    Filed
Herewith		    Incorporated by
Reference herein
from Form or
Schedule		    Filing Date    SEC File/
Reg. Number
  4.1.1    Restated Certificate of Incorporation of the Registrant, as amended.       S-3

(Exhibit 4.1.1)

    10/13/2017    333-220958
  4.1.2    Certificate of Designation of Series A Convertible Preferred Stock of the Registrant, filed with the Secretary of State of the State of Delaware on May 17, 2011.       8-K

(Exhibit 4.6)

    5/19/2011    001-33451
  4.1.3    Certificate of Designation of Series B Convertible Preferred Stock of the Registrant, filed with the Secretary of State of the State of Delaware on June 26, 2012.       8-K

(Exhibit 4.8)

    6/27/2012    001-33451
  4.2    Amended and Restated Bylaws of the Registrant.       S-8

(Exhibit 4.2)

    7/6/2007    333-144407
  4.3    Form of common stock certificate.       10-K

(Exhibit 4.1)

    12/22/2016    001-33451
  5.1    Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. with respect to the legality of the securities being registered.    X         
23.1    Consent of Ernst & Young LLP.    X         
23.2    Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in Exhibit 5.1).    X         
24.1    Powers of Attorney (included on the signature page to this registration statement).    X         
99.1    2018 Equity Incentive Plan.       10-Q

(Exhibit 10.1)

    8/9/2018    001-33451
99.2    Form of Stock Option Agreement under the 2018 Equity Incentive Plan.       10-Q

(Exhibit 10.2)

    8/9/2018    001-33451
99.3    Form of Restricted Stock Unit Agreement under the 2018 Equity Incentive Plan.       10-Q

(Exhibit 10.5)

    8/9/2018    001-33451
99.4    2018 Employee Stock Purchase Plan.       10-Q

(Exhibit 10.3)

    8/9/2018    001-33451

SIGNATURES

The Registrant. Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Commonwealth of Massachusetts, on August 9, 2018.

 

ALBIREO PHARMA, INC.
By:    /s/ Ronald H.W. Cooper
  Ronald H.W. Cooper
  President and Chief Executive Officer

SIGNATURES AND POWER OF ATTORNEY

We, the undersigned officers and directors of Albireo Pharma, Inc., hereby severally constitute and appoint Ronald H.W. Cooper, Thomas A. Shea and Jason G. Duncan, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Albireo Pharma, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

 

Signature

   

Title

  

Date

/s/ Ronald H.W. Cooper

Ronald H.W. Cooper

   

President, Chief Executive Officer and Director

(principal executive officer)

   August 9, 2018

/s/ Thomas A. Shea

Thomas A. Shea

   

Chief Financial Officer

(principal financial officer and principal accounting officer)

   August 9, 2018

/s/ David Chiswell, Ph.D.

David Chiswell, Ph.D.

    Chairman of the Board of Directors   August 9, 2018

/s/ Anne Klibanski, M.D.

Anne Klibanski, M.D.

    Director   August 9, 2018

/s/ Michael Gutch, Ph.D.

Michael Gutch, Ph.D.

    Director   August 9, 2018

/s/ Roger A. Jeffs, Ph.D.

Roger A. Jeffs, Ph.D.

    Director   August 9, 2018

/s/ Stephanie S. Okey, M.S.

Stephanie S. Okey, M.S.

    Director   August 9, 2018

/s/ Davey S. Scoon

Davey S. Scoon

    Director   August 9, 2018